Daejeon [South Korea], August 4 (ANI): The US Food and Drug Administration recently approved Aduhelm, a monoclonal antibody that targets amyloid beta (A), as the first Alzheimer's disease treatment (AD). Its impact on cognitive improvement, however, is controversial.
Daejeon [South Korea], August 4 (ANI): Aduhelm, a monoclonal antibody that targets amyloid beta (A), was recently found by the US Food and Drug Administration as the first treatment for Alzheimer's disease (AD). However, its impact on cognitive improvement is still debatable.